Comprehensive Care + 24 Hour Emergency

Immunoprofiling to Combat ITP

Yellow lab in a field

Autoimmune disease develops when the immune system "goes rogue" and destroys normal healthy cells in the body. Immune Thrombocytopenia (ITP) is a serious bleeding disorder caused by immune destruction of platelets, small blood cells that heal injured blood vessels. The treatment of ITP involves long courses of powerful immunosuppresive drugs that require frequent rechecks for monitoring. Common side effects of these drugs include urinary incontinence, hair loss, and intestinal ulcers, and can be as severe as bone marrow failure or sepsis.

Our study combines DNA analyses and immune cell profiling to understand the cause of immune-targeted platelet destruction. The results of this research will help veterinarians optimize treatment for each canine patient in order to minimize treatment side effects. This study is sponsored by the AKC Canine Health Foundation (CHF).

Eligibility: Dogs with severe thrombocytopenia, defined as a platelet count below 50,000/uL, and evidence of immune-mediated platelet destruction. The study sites include Cornell University Hospital for Animals (Ithaca, NY) as well as the following institutions:

Cornell University Veterinary Specialists (Stamford, CT)

Iowa State University College of Veterinary Medicine (Ames, IA)

Veterinary Specialists & Emergency Services (Rochester, NY)

Oradell Animal Hospital (Paramus, NJ)

Red Bank Veterinary Hospital (Tinton Falls, NJ)

Blue Pearl Veterinary Partners (Northfield, IL)

Arizona Veterinary Emergency and Critical Care Center (Gilbert, AZ)

Compensation: The study covers the costs of coagulation testing at the time of diagnosis.

Owner Responsibilities: You will be asked to allow collection of a one-time blood sample from your dog at the time of diagnosis of ITP. All subsequent medical therapy and monitoring is performed following standard of care, with no special procedures or therapy dictated by the study.

Principal Investigator: Marjory Brooks, DVM, DACVIM

Contact: For questions or more information on the study email the clinical trials coordinator at or call 607.253.3060.

Printable Flyer of this information